Evercore ISI analyst Elizabeth Anderson downgraded Health Catalyst to In Line from Outperform with a price target of $11, up from $10.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCAT:
- Health Catalyst to Participate in Upcoming Investor Conference
- Health Catalyst announces multi-year contract with Carle Health
- Health Catalyst CEO Daniel Burton buys 197,079 shares of stock
- Here’s Why Health Catalyst Stock (NASDAQ: HCAT) Surged Almost 30% Today
- Health Catalyst Reports Third Quarter 2022 Results